Electromechanical factors associated with favourable outcome in cardiac resynchronization therapy

Electromechanical coupling in patients receiving cardiac resynchronization therapy (CRT) is not fully understood. Our aim was to determine the best combination of electrical and mechanical substrates associated with effective CRT. Sixty-two patients were prospectively enrolled from two centres. Pati...

Full description

Saved in:
Bibliographic Details
Published inEuropace (London, England) Vol. 25; no. 2; pp. 546 - 553
Main Authors Maffessanti, Francesco, Jadczyk, Tomasz, Wilczek, Jacek, Conte, Giulio, Caputo, Maria Luce, Gołba, Krzysztof S, Biernat, Jolanta, Cybulska, Magdalena, Caluori, Guido, Regoli, François, Krause, Rolf, Wojakowski, Wojciech, Prinzen, Frits W, Auricchio, Angelo
Format Journal Article
LanguageEnglish
Published England Oxford University Press 16.02.2023
Subjects
Online AccessGet full text
ISSN1099-5129
1532-2092
1532-2092
DOI10.1093/europace/euac157

Cover

More Information
Summary:Electromechanical coupling in patients receiving cardiac resynchronization therapy (CRT) is not fully understood. Our aim was to determine the best combination of electrical and mechanical substrates associated with effective CRT. Sixty-two patients were prospectively enrolled from two centres. Patients underwent 12-lead electrocardiogram (ECG), cardiovascular magnetic resonance (CMR), echocardiography, and anatomo-electromechanical mapping (AEMM). Remodelling was measured as the end-systolic volume (ΔESV) decrease at 6 months. CRT was defined effective with ΔESV ≤ -15%. QRS duration (QRSd) was measured from ECG. Area strain was obtained from AEMM and used to derive systolic stretch index (SSI) and total left-ventricular mechanical time. Total left-ventricular activation time (TLVAT) and transeptal time (TST) were derived from AEMM and ECG. Scar was measured from CMR. Significant correlations were observed between ΔESV and TST [rho = 0.42; responder: 50 (20-58) vs. non-responder: 33 (8-44) ms], TLVAT [-0.68; 81 (73-97) vs. 112 (96-127) ms], scar [-0.27; 0.0 (0.0-1.2) vs. 8.7 (0.0-19.1)%], and SSI [0.41; 10.7 (7.1-16.8) vs. 4.2 (2.9-5.5)], but not QRSd [-0.13; 155 (140-176) vs. 167 (155-177) ms]. TLVAT and SSI were highly accurate in identifying CRT response [area under the curve (AUC) > 0.80], followed by scar (AUC > 0.70). Total left-ventricular activation time (odds ratio = 0.91), scar (0.94), and SSI (1.29) were independent factors associated with effective CRT. Subjects with SSI >7.9% and TLVAT <91 ms all responded to CRT with a median ΔESV ≈ -50%, while low SSI and prolonged TLVAT were more common in non-responders (ΔESV ≈ -5%). Electromechanical measurements are better associated with CRT response than conventional ECG variables. The absence of scar combined with high SSI and low TLVAT ensures effectiveness of CRT.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Francesco Maffessanti and Tomasz Jadczyk contributed equally to this work.
Conflict of interest: F.M. reports intellectual property with Biosense Webster. A.A. is a consultant to Boston Scientific, Backbeat, Biosense Webster, Cardiac, Corvia, Daiichi Sankyo, Medtronic, Merit, Microport CRM, Philips, and V-Wave; he received speakers’ fee from Daiichi Sankyo, Boston Scientific, Biosense Webster, Medtronic, Microport CRM, and Philips; he participated in clinical trials sponsored by Boston Scientific, Medtronic, Microport CRM, and Zoll Medical; he reports intellectual properties with Boston Scientific, Biosense Webster, and Microport CRM. F.W.P. has received research grants from Medtronic, Abbott, Microport CRM, Biotronik, and Biosense Webster and speakers fee from Medtronic, Abbott, and Microport CRM. He reports intellectual property with Boston Scientific, Medtronic, and Biosense Webster. K.S.G. received speakers’ fee from Medtronic and participated in clinical trials sponsored by Medtronic and Abbott. W.W. received lecture honorarium from the Biosense Webster. All other authors do not have disclosures.
ISSN:1099-5129
1532-2092
1532-2092
DOI:10.1093/europace/euac157